23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...
07:00 , Aug 7, 2014 |  BC Innovations  |  Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential...
07:00 , Oct 29, 2012 |  BioCentury  |  Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
08:00 , Dec 8, 2011 |  BC Innovations  |  Cover Story

Big MAC attack in osteoarthritis

An international research team has shown that inhibiting the complement system slows disease progression in mice with osteoarthritis, thus pointing to complement inhibitors as potential disease modifiers. 1 Although the findings offer companies developing inhibitors...
08:00 , Jan 30, 2006 |  BioCentury  |  Product Development

Indication finding

Neither of Alexion Pharmaceuticals Inc. 's two monoclonal antibodies against complement 5 have had an easy road. But the company finally seems to have discovered the right indication for one of them, reporting last week...
07:00 , Oct 11, 2004 |  BioCentury  |  Product Development

The heart of inflammation

Inflammation is a complex network of interactions that arises in response to tissue injury, regardless of the site or nature of the initiating event. Despite this virtual omnipresence of the inflammatory process throughout the body,...
08:00 , Feb 25, 2002 |  BioCentury  |  Product Development

Complementary difficulties

The failure of TP10 from Avant Immunotherapeutics Inc. to meet its primary endpoint in a Phase II trial of patients undergoing cardiac surgery is the second such setback for a compound targeting complement in a...
07:00 , Oct 9, 1995 |  BC Week In Review  |  Clinical News

Alexion preclinical data

Alexion's lead complement inhibitor, 5G1.1-SC, was effective in blocking the complement cascade in an ex vivo model of cardiopulmonary bypass, in which human blood was run through a bypass machine. The results, published in the...